| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/01/2004 | US20040127489 Novel antipsychotic combination therapies and compositions useful therein |
| 07/01/2004 | US20040127485 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists |
| 07/01/2004 | US20040127482 Substituted heterocycle fused gamma-carbolines |
| 07/01/2004 | US20040127481 Administering a therapeutic amount of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride condensation aerosol |
| 07/01/2004 | US20040127474 Contacting the cell with a ptc agonist in a sufficient amount to inhibit the altered growth state, wherein the ptc agonist is a organic molecule having a molecular weight less than about 750 amu for inhibiting an altered growth state of a cell |
| 07/01/2004 | US20040127468 phosphatidic acid decreases apoptosis induced by the sudden withdrawal of NGF and serum (trophic withdrawal), rotenone, and glutamate |
| 07/01/2004 | US20040127452 C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them |
| 07/01/2004 | US20040127438 polypeptide (or its encoding nucleic acid molecule from Mycobacterium tuberculosis or related prokaryotes in the treatment of cancer, allergic disorders or conditions of immunoactivation, particularly asthma |
| 07/01/2004 | US20040127419 Methods of using truncated glial cell line-derived neurotrophic factor |
| 07/01/2004 | US20040126878 Method for the preparation of immunologically inert amniotic membranes |
| 07/01/2004 | US20040126799 First nucleotide sequence comprises adenine residue at position 1033 or equivalent; reducing disease treatment side effects |
| 07/01/2004 | US20040126759 Molecules for disease detection and treatment |
| 07/01/2004 | US20040126397 Neuromuscular disorders |
| 07/01/2004 | US20040126396 Pain therapy; administering neurotoxins |
| 07/01/2004 | US20040126366 Autism, attention deficit , obsessive complusive disorders , mental retardation |
| 07/01/2004 | US20040126359 Modulate lymphocyte activation; cell proliferation; apoptosis; signal transduction |
| 07/01/2004 | US20040126330 Nicotine-containing film preparation |
| 07/01/2004 | US20040126329 Delivery of analgesics through an inhalation route |
| 07/01/2004 | US20040126328 Arerosol; heating drug, vaporization, cooling |
| 07/01/2004 | US20040126327 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 07/01/2004 | US20040126326 Delivery of antidepressants through an inhalation route |
| 07/01/2004 | US20040126324 Mixture of ion exchange resin and drug |
| 07/01/2004 | US20040126323 Transdermal dosage form comprising an active agent and a salt and free-base form of an adverse agent |
| 07/01/2004 | DE10261807A1 Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel Deuterated catecholamine derivatives and pharmaceutical compositions containing them |
| 07/01/2004 | DE10261131A1 Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide Substituted 5-aminomethyl-1H-pyrrole-2-carboxylic acid |
| 07/01/2004 | DE10261091A1 Gesättigte und ungesättigte Heteroarylcycloalkylmethyl-Amine Saturated and unsaturated amines Heteroarylcycloalkylmethyl |
| 07/01/2004 | DE10259382A1 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung 3-substituted 3,4-dihydro-thieno [2,3-d] pyrimidin-4-one derivatives, their preparation and use |
| 07/01/2004 | CA2510322A1 2-pyridyl and 2-pyrimidyl cycloalkylene amide compounds as nr2b receptor antagonists |
| 07/01/2004 | CA2509633A1 3h-quinazolin-4-one derivatives |
| 07/01/2004 | CA2509616A1 Combination therapy for the treatment of pain |
| 07/01/2004 | CA2509615A1 Gabapentin analogues for fibromyalgia and other related disorders |
| 07/01/2004 | CA2509611A1 Method of treatment for sexual dysfunction |
| 07/01/2004 | CA2509600A1 Pharmaceutical uses for alpha2delta ligands |
| 07/01/2004 | CA2509104A1 5-aminophenanthridine derivatives as npy-5 antagonists |
| 07/01/2004 | CA2508855A1 Valproic acid analogues and pharmaceutical compositions thereof |
| 07/01/2004 | CA2508297A1 Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| 07/01/2004 | CA2508045A1 Novel compounds having selective inhibiting efect at gsk3 |
| 07/01/2004 | CA2505788A1 Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
| 06/30/2004 | EP1434053A1 Reagent for detecting risk factor for alzheimer's disease, detection kit therefor and method of detecting risk factor for alzheimer's disease using the same |
| 06/30/2004 | EP1433783A2 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 06/30/2004 | EP1433781A1 Pyrrolidine carboxylic acid derivatives |
| 06/30/2004 | EP1433480A1 Medicine containing pyrimidine derivative |
| 06/30/2004 | EP1432991A1 Identification and isolation of somatic stem cells and uses thereof |
| 06/30/2004 | EP1432801A2 Receptors and membrane-associated proteins |
| 06/30/2004 | EP1432724A1 Rna interference mediated inhibition of map kinase genes |
| 06/30/2004 | EP1432723A2 Modulation of the expression of genes dependent on stat-1 |
| 06/30/2004 | EP1432708A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity |
| 06/30/2004 | EP1432707A1 Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| 06/30/2004 | EP1432703A1 Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| 06/30/2004 | EP1432702A1 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors |
| 06/30/2004 | EP1432701A1 Heterocyclic compounds for use in the treatment of disorders of the urinary tract |
| 06/30/2004 | EP1432700A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 06/30/2004 | EP1432699A1 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 06/30/2004 | EP1432697A1 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 06/30/2004 | EP1432696A1 Chroman derivatives as 5-hydroxytryptamine-6 ligands |
| 06/30/2004 | EP1432693A2 Mch receptor antagonists |
| 06/30/2004 | EP1432691A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
| 06/30/2004 | EP1432686A1 Tetrahydroisochinolines, their production and the use thereof as analgesics |
| 06/30/2004 | EP1432679A1 Preparation and use of pyrrole derivatives for treating obesity |
| 06/30/2004 | EP1432674A2 Hydroxypropylamines |
| 06/30/2004 | EP1432453A1 Stilbene derivatives and their use for binding and imaging amyloid plaques |
| 06/30/2004 | EP1432452A2 Inhibition of stat-1 |
| 06/30/2004 | EP1432444A2 Anti-a-beta antibodies |
| 06/30/2004 | EP1432435A1 Enamel matrix protein compositions for modulating immune response |
| 06/30/2004 | EP1432424A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions |
| 06/30/2004 | EP1432420A2 Benzimidazolidinone derivatives as muscarinic agents |
| 06/30/2004 | EP1432419A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers |
| 06/30/2004 | EP1432416A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/30/2004 | EP1432408A1 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 06/30/2004 | EP1432407A1 Lisinopril compositions having large-particle dcpd |
| 06/30/2004 | EP1432379A1 Methods for inhibiting cognitive deterioration in adults with down's syndrome |
| 06/30/2004 | EP1315730B1 1-(alkyl), 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo(1,2-a)pyrimidin-5(1h)-one derivatives |
| 06/30/2004 | EP1282625B1 Benzoxazines for use in the treatment of parkinson's disease |
| 06/30/2004 | EP1237524A4 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| 06/30/2004 | EP1214313B1 Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same |
| 06/30/2004 | EP1178982B1 Heterocyclic substituted aminoazacycles useful as central nervous system agents |
| 06/30/2004 | EP1045693B1 Aminophenoxyacetic acid derivatives as neuroprotectants |
| 06/30/2004 | EP1019408B1 1,2,3,4-TETRAHYDRO-BENZOFURO[3,2-c]PYRIDINE DERIVATIVES |
| 06/30/2004 | EP0977560B1 IBUPROFEN THIOESTERS AS INHIBITORS OF Nf-kappaB-DEPENDENT PAIN AND INFLAMMATION MEDIATOR FORMATION |
| 06/30/2004 | EP0971908B1 Il-8 receptor antagonists |
| 06/30/2004 | EP0939630B1 Use of benzopyranols to treat neurological disorders |
| 06/30/2004 | CN1509337A New polynucleotides and polypeptides of IFN alpha-17 gene |
| 06/30/2004 | CN1509333A Novel neurotrophic factors |
| 06/30/2004 | CN1509290A Process for synthesis of derivatives of 2,30dihydro-1,4-dioxino-[2,3-f]quinoline |
| 06/30/2004 | CN1509289A Imidazo[1,5,-A] pyrimido[5,4-d]benzazepine derivatives as GABAA receptor medulators |
| 06/30/2004 | CN1509288A The citrate salt of 5,8,14-triazatetracyclo (10.3.1.0.2,11.0.4,9)-hexadeca-2.(11),3,5,7,9-pentaene |
| 06/30/2004 | CN1509287A Aryl-8-azabicyclo[3,2,1]octanes for treating depression |
| 06/30/2004 | CN1509286A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509282A 4-(phenyl-piperdin-4-ylidene-methyl)benzamide derivatives and theive use for treating pain, anxiety or gastrointestinal disorders |
| 06/30/2004 | CN1509281A Benzimidazol derivatives modulate che mokine receptors |
| 06/30/2004 | CN1509279A Process for production of citalopram |
| 06/30/2004 | CN1509276A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509275A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509274A Metallo proteinase inhibitors |
| 06/30/2004 | CN1509273A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509272A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509271A 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for treatment of pain anxiety or gastrointestinal disorders |
| 06/30/2004 | CN1509269A 磺酰胺衍生物 Sulfonamide derivatives |
| 06/30/2004 | CN1509196A 4(2-butylamino)-2,7-dimethyl-8-(2-methyl(-6-methoxyp-3-yl)pyrazolo-[1,5-A]-1,3,5-triazine as corticotropin releasing factor receptor |
| 06/30/2004 | CN1509181A Composition contaiuing asiasari radix extracts for protecting brain cells and improving memory |